Bardoux Pascale, Bruneval Patrick, Heudes Didier, Bouby Nadine, Bankir Lise
INSERM Unité 367, Institut du Fer à Moulin and INSERM Unité 430, Hôpital Broussais, Paris, France.
Nephrol Dial Transplant. 2003 Sep;18(9):1755-63. doi: 10.1093/ndt/gfg277.
Vasopressin, an antidiuretic hormone, is elevated in diabetes mellitus (DM). The aim of this study was to evaluate whether the V(2) receptor-mediated actions of vasopressin contribute to the albuminuria of diabetes.
Fourteen adult male Wistar rats with streptozotocin-induced DM were treated over 9 weeks with a selective, non-peptide, orally active V(2) receptor antagonist (SR 121463) and were compared to 14 untreated diabetic rats (control). The dose of antagonist was adapted in order to maintain urine osmolality close to plasma osmolality, but not to induce the formation of hypoosmotic urine. Every second week, urine was collected in metabolic cages for two 24 h periods.
Urinary albumin excretion (UAE) rose regularly and significantly with time in the untreated control group, whereas it did not rise in treated rats. Interestingly, a variable pattern of UAE increase over time was observed in different rats of the control group. Some rats exhibited pronounced progression of albuminuria with time, while others showed no or only a very modest rise. An a posteriori partition of the control group into 'progressors' and 'non-progressors' revealed that progressors had more intense urinary concentrating activity, higher creatinine clearance and larger relative glomerular mesangial area than the other subgroup.
This study shows that V(2) receptor-mediated actions of vasopressin play a critical role in the albuminuria of diabetes. It also reveals that individual rats, like humans, seem to exhibit an unequal susceptibility to diabetic nephropathy, or at least to albuminuria, a factor considered to be one of its early manifestations.
抗利尿激素血管加压素在糖尿病(DM)中水平升高。本研究旨在评估血管加压素V₂受体介导的作用是否导致糖尿病患者蛋白尿。
14只成年雄性Wistar大鼠经链脲佐菌素诱导患糖尿病,用选择性、非肽类、口服活性V₂受体拮抗剂(SR 121463)治疗9周,并与14只未治疗的糖尿病大鼠(对照组)进行比较。调整拮抗剂剂量以维持尿渗透压接近血浆渗透压,但不诱导低渗尿形成。每隔一周,在代谢笼中收集尿液,为期两个24小时。
在未治疗的对照组中,尿白蛋白排泄量(UAE)随时间有规律且显著升高,而在治疗组大鼠中未升高。有趣的是,在对照组的不同大鼠中观察到UAE随时间增加的模式各异。一些大鼠蛋白尿随时间有明显进展,而另一些大鼠则无升高或仅轻微升高。将对照组事后分为“进展者”和“非进展者”,结果显示,进展者比另一亚组有更强的尿液浓缩活性、更高的肌酐清除率和更大的相对肾小球系膜面积。
本研究表明,血管加压素V₂受体介导的作用在糖尿病蛋白尿中起关键作用。它还揭示,个体大鼠与人类一样,似乎对糖尿病肾病,或至少对被认为是其早期表现之一的蛋白尿具有不同的易感性。